Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 15 10 2018
revised: 28 03 2019
accepted: 14 06 2019
pubmed: 27 6 2019
medline: 17 6 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

To define transcriptional dependencies of triple-negative breast cancer (TNBC), we identified transcription factors highly and specifically expressed in primary TNBCs and tested their requirement for cell growth in a panel of breast cancer cell lines. We found that

Identifiants

pubmed: 31239270
pii: 0008-5472.CAN-18-3264
doi: 10.1158/0008-5472.CAN-18-3264
pmc: PMC6698222
mid: NIHMS1532762
doi:

Substances chimiques

Co-Repressor Proteins 0
EN1 protein, human 0
Homeodomain Proteins 0
TLE3 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

4173-4183

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197623
Pays : United States
Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

©2019 American Association for Cancer Research.

Références

Nucleic Acids Res. 2000 Sep 15;28(18):3442-4
pubmed: 10982861
Bioinformatics. 2001 Oct;17(10):977-87
pubmed: 11673243
Development. 2004 Jul;131(13):3229-36
pubmed: 15175251
Ann Surg Oncol. 2005 Jun;12(6):488-96
pubmed: 15864483
Mol Biol Cell. 2006 Jun;17(6):2572-80
pubmed: 16571670
Dev Biol. 2006 Aug 1;296(1):164-76
pubmed: 16730693
Methods Mol Biol. 2007;356:319-50
pubmed: 16988414
J Comput Graph Stat. 2010 Jun 1;9(2):332-353
pubmed: 20953302
PLoS One. 2011 Mar 21;6(3):e17911
pubmed: 21445301
Proc Natl Acad Sci U S A. 2011 May 17;108(20):8212-7
pubmed: 21531907
Neural Dev. 2011 May 10;6:23
pubmed: 21569278
Int J Dev Biol. 2011;55(4-5):439-45
pubmed: 21858769
Nat Neurosci. 2011 Sep 04;14(10):1260-6
pubmed: 21892157
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Eur J Neurosci. 2012 Jun;35(12):1837-45
pubmed: 22708594
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Development. 2013 Mar;140(6):1342-52
pubmed: 23444360
Development. 2013 Aug;140(16):3373-84
pubmed: 23863478
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Oncogene. 2014 Sep 25;33(39):4767-77
pubmed: 24141779
Biomark Med. 2013 Dec;7(6):893-901
pubmed: 24266821
Science. 2015 Apr 17;348(6232):aaa2151
pubmed: 25883361
Cell. 2015 May 7;161(4):803-16
pubmed: 25913192
Cell Rep. 2015 Jun 16;11(10):1549-63
pubmed: 26051943
IUBMB Life. 2015 Jul;67(7):472-81
pubmed: 26172616
Genome Res. 2016 Mar;26(3):385-96
pubmed: 26843070
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
R J. 2016 Aug;8(1):289-317
pubmed: 27818791
Am J Pathol. 2017 Oct;187(10):2152-2162
pubmed: 28733194
Nat Commun. 2018 Jun 13;9(1):2311
pubmed: 29899353
Nat Commun. 2018 Nov 27;9(1):5007
pubmed: 30479348
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Nature. 1996 Sep 26;383(6598):332-4
pubmed: 8848044

Auteurs

Guillermo Peluffo (G)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Ashim Subedee (A)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
BBS Program, Harvard Medical School, Boston, Massachusetts.

Nicholas W Harper (NW)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.

Natalie Kingston (N)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.

Bojana Jovanović (B)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Felipe Flores (F)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Harvard University, Cambridge, Massachusetts.

Laura E Stevens (LE)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Francisco Beca (F)

Department of Pathology, Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Anne Trinh (A)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Chandra Sekhar Reddy Chilamakuri (CSR)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Evangelia K Papachristou (EK)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Katherine Murphy (K)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.

Ying Su (Y)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Andriy Marusyk (A)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Clive S D'Santos (CS)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Oscar M Rueda (OM)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Andrew H Beck (AH)

Department of Pathology, Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Carlos Caldas (C)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Jason S Carroll (JS)

Cambridge Research Institute, University of Cambridge, Cambridge, United Kingdom.

Kornelia Polyak (K)

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Massachusetts. kornelia_polyak@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
BBS Program, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH